▲ 1.23%
prev close
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
+1
1 buys · 0 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-06-09 | SNNSmith & Nephew SNATS, Inc. Common Stock | Buy | $1,001 - $15,000 | 433d ago | — |
2025-06-09
Lisa McClain
SNN
Amount
$1,001 - $15,000
Filed
433d ago
Recent News
Powered by Polygon.io
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets
Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo.
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care
Explosive Growth in AI for Orthopedic Surgery Market: $0.87 Billion by 2030 at 27.2% CAGR
Trade Timeline
Congressional activity, newest first
Lisa McClain
2025-06-09 · Purchase
$1,001 - $15,000